Foundation Medicine (FMI) : 6 analysts are covering Foundation Medicine (FMI) and their average rating on the stock is 2.67, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Foundation Medicine (FMI) : 3 Wall Street analysts covering Foundation Medicine (FMI) believe that the average level the stock could reach for the short term is $17.67. The maximum price target given is $23 and the minimum target for short term is around $15, hence the standard deviation is calculated at $4.62.
Foundation Medicine (NASDAQ:FMI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $20.38 and $20.38 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $21.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $21.08, notching a gain of 3.89% for the day. The total traded volume was 404,425 . The stock had closed at $20.29 on the previous day.
The company shares have dropped -37.45% from its 1 Year high price. On Jul 8, 2015, the shares registered one year high at $36.70 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $19.00 and the 200 Day Moving Average price is recorded at $17.43.
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patients individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products, FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and various sarcomas and pediatric cancers, are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.